Selective glucocorticoid receptor (GR-II) antagonist reduces body weight gain in mice

Journal of Nutrition and Metabolism

Volumn 2011, Issue , 2011, Pages

  Asagami, Tomoko ^a   Belanoff, Joseph K ^a,b   Azuma, Junya ^a   Blasey, Christine M ^a,b   Clark, Robin D ^b   Tsao, Philip S ^a  

^a STANFORD UNIVERSITY   (United States)

^b Corcept Therapeutics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; MUS;

EID: 84873802435     PISSN: 20900724     EISSN: 20900732     Source Type: Journal    
DOI: 10.1155/2011/235389     Document Type: Article

References (21)

1. Flegal K. M., Carroll M. D., Ogden C. L., Curtin L. R., Prevalence and trends in obesity among US adults, 1999-2008. Journal of the American Medical Association 2010 303 3 235 241 2-s2.0-74549140993 10.1001/jama.2009.2014
2. Andrews R. C., Walker B. R., Glucocorticoids and insulin resistance: old hormones, new targets. Clinical Science 1999 96 5 513 523 2-s2.0-0032936343 10.1042/CS19980388 (Pubitemid 29237902)
3. Chrousos G. P., The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. International Journal of Obesity 2000 24 2 S50 S55 2-s2.0-0033940092 10.1038/sj/ijo/0801278 (Pubitemid 30461948)
4. Orth D. N., Medical progress: cushing's syndrome. New England Journal of Medicine 1995 332 12 791 803 2-s2.0-0029650769 10.1056/NEJM199503233321207
5. Nieman L. K., Biller B. M. K., Findling J. W., Newell-Price J., Savage M. O., Stewart P. M., Montori V. M., Edwards H., The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 5 1526 1540 2-s2.0-43249095400 10.1210/jc.2008-0125 (Pubitemid 351656485)
6. Anagnostis P., Athyros V. G., Tziomalos K., Karagiannis A., Mikhailidis D. P., The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. Journal of Clinical Endocrinology and Metabolism 2009 94 8 2692 2701 2-s2.0-68549139946 10.1210/jc.2009-0370
7. Lindholm J., Juul S., Jørgensen J. O. L., Astrup J., Bjerre P., Feldt-Rasmussen U., Hagen C., Jørgensen J., Kosteljanetz M., Kristensen L. Ø., Laurberg P., Schmidt K., Weeke J., Incidence and late prognosis of Cushing's syndrome: a population-based study. Journal of Clinical Endocrinology and Metabolism 2001 86 1 117 123 2-s2.0-17744362051 10.1210/jc.86.1.117 (Pubitemid 32111743)
8. Dinneen S., Alzaid A., Miles J., Rizza R., Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. Journal of Clinical Investigation 1993 92 5 2283 2290 2-s2.0-0027358385 (Pubitemid 23333534)
9. Rooney D. P., Neely R. D.G., Cullen C., Ennis C. N., Sheridan B., Atkinson A. B., Trimble E. R., Bell P. M., The effect of cortisol on glucose/glucose-6-phosphate cycle activity and insulin action. Journal of Clinical Endocrinology and Metabolism 1993 77 5 1180 1183 10.1210/jc.77.5.1180 (Pubitemid 23345466)
10. Rizza R. A., Mandarino L. J., Gerich J. E., Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. Journal of Clinical Endocrinology and Metabolism 1982 54 1 131 138 2-s2.0-0020469555 (Pubitemid 13242146)
11. Nieman L. K., Chrousos G. P., Kellner C., Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU486. Journal of Clinical Endocrinology and Metabolism 1985 61 536 540 10.1210/jc.2008-0125 (Pubitemid 15243969)
12. Biller B. M. K., Grossman A. B., Stewart P. M., Melmed S., Bertagna X., Bertherat J., Buchfelder M., Colao A., Hermus A. R., Hofland L. J., Klibanski A., Lacroix A., Lindsay J. R., Newell-Price J., Nieman L. K., Petersenn S., Sonino N., Stalla G. K., Swearingen B., Vance M. L., Wass J. A. H., Boscaro M., Treatment of adrenocorticotropin-dependent cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2008 93 7 2454 2462 2-s2.0-47549104969 10.1210/jc.2007-2734 (Pubitemid 352008503)
13. Johanssen S., Allolio B., Mifepristone (RU 486) in Cushing's syndrome. European Journal of Endocrinology 2007 157 5 561 569 2-s2.0-36549032804 10.1530/EJE-07-0458 (Pubitemid 350187372)
14. Bertagna X., Bertagna C., Laudat M. H., Girard F., Luton J. P., Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1986 63 3 639 643 (Pubitemid 16050563)
15. Chu J. W., Matthias D. F., Belanoff J., Schatzberg A., Hoffman A. R., Feldman D., Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). Journal of Clinical Endocrinology and Metabolism 2001 86 8 3568 3573 2-s2.0-0034880195 10.1210/jc.86.8.3568 (Pubitemid 32755945)
16. Castinetti F., Fassnacht M., Johanssen S., Terzolo M., Bouchard P., Chanson P., Cao C. D., Picó A., Ouzounian S., Young J., Hahner S., Brue T., Allolio B., Conte-Devolx B., Merits and pitfalls of mifepristone in Cushing's syndrome. European Journal of Endocrinology 2009 160 6 1003 1010 2-s2.0-66149129124 10.1530/EJE-09-0098
17. Gross C., Blasey C. M., Roe R. L., Belanoff J. K., Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity 2010 18 2 2295 2300 2-s2.0-77949703780 10.1038/oby.2010.51
18. Gross C., Blasey C. M., Roe R. L., Allen K., Block T. S., Belanoff J. K., Mifepristone treatment of olanzapine-induced weight gain in healthy men. Advances in Therapy 2009 26 10 959 969 2-s2.0-73949134203 10.1007/s12325-009- 0070-1
19. Belanoff J. K., Blasey C. M., Clark R. D., Roe R. L., Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain. Diabetes, Obesity and Metabolism 2010 12 6 545 547 2-s2.0-77953220891 10.1111/j.1463-1326.2009.01185.x
20. Clark R. D., Ray N. C., Williams K., Blaney P., Ward S., Crackett P. H., Hurley C., Dyke H. J., Clark D. E., Lockey P., Devos R., Wong M., Porres S. S., Bright C. P., Jenkins R. E., Belanoff J., 1H-Pyrazolo[3,4-g] hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity. Bioorganic and Medicinal Chemistry Letters 2008 18 4 1312 1317 2-s2.0-38949215790 10.1016/j.bmcl.2008.01.027 (Pubitemid 351226546)
21. Beebe K. L., Block T., DeBattista C., Blasey C., Belanoff J. K., The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behavioural Brain Research 2006 171 2 225 229 2-s2.0-33745362873 10.1016/j.bbr.2006.03.039 (Pubitemid 43946497)